The estimated Net Worth of Christopher P Kiritsy is at least $442 Тысяча dollars as of 25 May 2023. Mr. Kiritsy owns over 10,000 units of Pieris Pharmaceuticals Inc stock worth over $349,800 and over the last 8 years he sold PIRS stock worth over $0. In addition, he makes $92,573 as Independent Director at Pieris Pharmaceuticals Inc.
Christopher has made over 3 trades of the Pieris Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of PIRS stock worth $8,500 on 25 May 2023.
The largest trade he's ever made was buying 10,000 units of Pieris Pharmaceuticals Inc stock on 25 May 2023 worth over $8,500. On average, Christopher trades about 1,429 units every 159 days since 2016. As of 25 May 2023 he still owns at least 20,000 units of Pieris Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kiritsy stock trades at the bottom of the page.
Christopher P. Kiritsy serves as Independent Director of the Company. Mr. Kiritsy joined the Board of Directors of Pieris in September 2016. Mr. Kiritsy is founder and managing member of Precision Kapital, LLC, a private investment and advisory firm. Prior to forming Precision Kapital, Mr. Kiritsy co-founded Arisaph Pharmaceuticals, Inc. ("Arisaph"), and served as Arisaph’s President and Chief Executive Officer from 2005 through March 2018. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc. ("Kos"), where he played a key operating role in building the company from start-up to a highly profitable, publicly traded, commercial company. During his 10-year tenure at Kos, Mr. Kiritsy spearheaded more than 10 major corporate development transactions and raised approximately $500 million in public equity, including Kos’ initial public offering. Kos was acquired by Abbott Laboratories for $4 billion in 2016. Mr. Kiritsy previously served as a Board member and Audit Committee Chair of Melinta Pharmaceuticals, Inc., as a Board member of Arisaph. and as Chairman of the Board of Avaxia Biologics, Inc. Mr. Kiritsy is a seasoned entrepreneur, who possesses more than 20 years of business and technical experience, previously holding senior management positions in R&D, business development and finance.
As the Independent Director of Pieris Pharmaceuticals Inc, the total compensation of Christopher Kiritsy at Pieris Pharmaceuticals Inc is $92,573. There are 8 executives at Pieris Pharmaceuticals Inc getting paid more, with Stephen Yoder having the highest compensation of $1,593,600.
Christopher Kiritsy is 55, he's been the Independent Director of Pieris Pharmaceuticals Inc since 2016. There are 5 older and 12 younger executives at Pieris Pharmaceuticals Inc. The oldest executive at Pieris Pharmaceuticals Inc is Peter Kiener, 68, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... и Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: